A Universal Mechanism of Action
Recce’s New Class of Synthetic Anti-Infectives have a universal mechanism of action with the ability to overcome hyper-cellular mutation of bacteria and viruses. Recce anti-infectives are unique – their potency does not diminish even with repeated use, a common failure associated with existing drugs.
Recce Pharmaceuticals have developed three primary drug candidates:
- RECCE® 327 and RECCE® 435 (bacterial infections); and
- RECCE® 529 (viral infections).
Recce Pharmaceuticals continues to strengthen and expand its product pipeline of therapeutic options for ‘difficult to treat’ bacterial and viral infections - including their mutated forms.